Psilocybin
2021P000863
Phase 2 small_molecule terminated
Quick answer
Psilocybin for Treatment-Resistant Major Depressive Disorder is a Phase 2 program (small_molecule) at Compass Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Compass Therapeutics
- Indication
- Treatment-Resistant Major Depressive Disorder
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated